Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.
In this episode of Skinfluenced: The Skin Podcast, we review Johnson & Johnson’s recent announcement seeking FDA approval for Icotrokinra — a promising new oral medication designed to revolutionize treatment for adults and adolescents with active, moderate-to-severe Plaque Psoriasis.
Tune in to learn how this novel oral IL-23 medication works, its potential to offer a novel approach in managing inflammation and safety data, and what this could mean for patients struggling with moderate-to-severe plaque psoriasis who need new treatment options beyond current therapies.
We’ll break down the drug’s mechanism, the clinical data that supports its use, and how it fits into the evolving landscape of dermatologic care.
Link to Source(s):
Johnson & Johnson Seeks First icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigmfor Adults and Adolescents With Plaque Psoriasis: https://s203.q4cdn.com/636242992/files/doc_news/Johnson--Johnson-seeks-first-icotrokinra-U-S--FDA-approval-aiming-to-revolutionize-treatment-paradigm-for-adults-and-adolescents-with-ABQBI.pdf
#PlaquePsoriasis #Psoriasis #Icotrokinra #IL23Inhibitor #IL23 #NPF #JohnsonAndJohnson #InflammatorySkinDisease #OralTherapiesForPsO #ChronicSkinDisease #BiologicAlternatives #NewFDADrugApproval #SkinBarrierRepair #SkinScience #Dermatology #DermatologyProvider #CosmeticDermatology #Aesthetics #Dermatologist #PhysicianAssistant #PhysicianAssociate #NursePractitioner #DermatologyPodcast #SkinfluencedPodcast